Join
Live feed
·
PRReleasevia Quantisnow
BioNTech SE logo

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer

ByQuantisnow·Wall Street's wire, on your screen.
BNTX· BioNTech SE
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BNTX (BioNTech SE) and more on Quantisnow.